Abstract Standard first-line chemotherapy results in disease progression and death within one year in most patients with human epidermal growth factor receptor 2 (HER2)-negative gastro-oesophageal adenocarcinoma 1–4 . Nivolumab plus chemotherapy demonstrated superior overall survival versus chemothe...
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!